Exclusivity Extension

Shield Therapeutics PLC (AIM:STX) saw its shares rise to 10.14p, a 5 % increase, after the U.S. FDA granted an additional three‑year extension of data exclusivity for its flagship product Accrufer. The new protection, effective until December 19 2028, augments existing patent coverage that extends into the mid‑2030s, thereby extending the company’s market monopoly on Accrufer.